UPDATE: Inovio Pharma (INO) CEO Targets Zika Vaccine Testing in Humans This Year - Bloomberg

---

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

---

(Updated - January 28, 2016 3:41 PM EST)

Inovio Pharma (NASDAQ: INO) CEO J. Joseph Kim said in a phone interview with Bloomberg that it plans to start testing its DNA-based Zika vaccine in non-human primates. Currently the vaccine is being tested on lab mice, but it is able to move faster than traditional vaccine development timelines. Testing in humans is targeted for this year.

Kim has been in talks with U.S. agencies about a potential Zika vaccine, and he sees getting extensive funding from U.S. agencies and abroad.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Exxon Mobil (XOM) annual Shareholders Meeting highlights company’s plans to play a leading role in the energy transition
• Geovax Labs Inc. (GOVX) Prices $20M Direct and PIPE Offerings at $1.65/sh
• Maxar Technologies Ltd. (MAXR) Shares Surge on Multi-Billion Dollar EOCL Award and Updated Guidance